Effects of a Novel Platelet Nitric Oxide Donor (LA816), Aspirin, Clopidogrel, and Combined Therapy in Inhibiting Flow- and Lesion-Dependent Thrombosis in the Porcine Ex Vivo Model
- 21 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (12) , 1686-1693
Abstract
Background— Acetylsalicylic acid (ASA), or aspirin, plus clopidogrel is becoming the standard antithrombotic treatment in people with coronary disease. Novel approaches such as the use of platelet-selective nitric oxide (NO) donors may provide additional protection against thrombosis. We evaluated the antithrombotic properties of a novel platelet-selective NO donor (LA816) administered alone and in combination with ASA, clopidogrel, or ASA+clopidogrel. Methods and Results— Thrombogenicity was measured in the porcine experimental model and assessed as platelet-thrombus formation in the ex vivo Badimon perfusion chamber. Pigs were randomly divided into 4 groups: (1) placebo control, (2) clopidogrel, (3) ASA, and (4) ASA+clopidogrel (ASA and clopidogrel were given orally, 10 mg · kg −1 · d −1 for 3 d). The animals were anesthetized, heparinized, and catheterized, and the Badimon perfusion chamber was placed in an extracorporeal shunt. After baseline perfusions, all animal groups received the intravenous infusion of LA816 for 2 hours. Platelet aggregation, blood pressure, and heart rate also were evaluated during the experiments. LA816, clopidogrel, and ASA+clopidogrel produced a reduction of ≈45% on thrombus mass versus placebo control perfusions ( P P Conclusions— Acute NO donation with LA816, without modifying hemodynamic parameters, provides the same inhibitory effect as that obtained with chronic treatment with clopidogrel+ASA. Moreover, LA816 provides platelet inhibitory effects in addition to those of the combined blockade of cyclooxygenase and P2y(12) receptor.Keywords
This publication has 29 references indexed in Scilit:
- Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effectsCardiovascular Research, 2004
- Platelet ADP receptors contribute to the initiation of intravascular coagulationBlood, 2004
- RhoA is required for cortical retraction and rigidity during mitotic cell roundingJournal of Cell Biology, 2003
- Novel Role for Low Molecular Weight Plasma Thiols in Nitric Oxide-mediated Control of Platelet FunctionJournal of Biological Chemistry, 2002
- P2Y12, a New Platelet ADP Receptor, Target of ClopidogrelBiochemical and Biophysical Research Communications, 2001
- Nitric Oxide Reverses Aspirin Antagonism of t-PA Thrombolysis in a Rabbit Model of Thromboembolic StrokeExperimental Neurology, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Platelet Activation in Acute Myocardial Infarction and Unstable Angina Is Inhibited by Nitric Oxide DonorsArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988